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Copper (II) complexes, namely dichloromono(1-amidino-O-ethylurea)copper (II), (1) and bis(1-amidino-O-ethylurea)copper 
(II) bromide, (2) were synthesized and characterized. The antibacterial screening of complexes 1 and 2 was performed along 
with their corresponding metal salts (CuCl2.2H2O) and (CuBr2), and ligand (dicyandiamide), against two human urinary 
pathogenic bacterial strains, Escherichia coli and Proteus mirabilis, by the disc diffusion method. All test compounds, except 
ligand have shown significant antibacterial activities on both bacterial strains. Their antibacterial effectiveness increased in a 
dose dependent manner, whereas their ability to inhibit the growth of both bacterial species decreased as their incubation time 
increased. The activity of complex 1 was found to be greater than its metal salt, while that of complex 2 was lower than the 
corresponding metal salt on both bacterial species. The in-vitro cytotoxic screening of complexes 1 and 2 was also assessed 
against human cervical adenocarcinoma cancer (HeLa) cell line using the MTT assay. Both complexes 1 and 2 have displayed 
cytotoxic effect in a dose-dependent manner with IC50 values of 59.64±6.68 µg/mL and 62.85±0.39 µg/mL, respectively. 
Overall, the highest antibacterial and cytotoxic activity of the present work is provided by complex 1. 
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Despite the extensive advances in scientific research and 
findings, infectious diseases remain one of the common 
health issues
1,2
. Considerable research effort has been 
directed globally in the search for novel drugs which can 
overcome the emergence of infectious and multidrug- 
resistance pathogenic microbes
3-6
. According to WHO, 
around 75% of the newly authorized drugs, which are 
under clinical trials, are derivatives of already approved 
compounds. Regardless of the fact that their multiple 
resistance mechanisms are well established, the clinical 
benefits are still limited
7
.  
Cancer is a major life-threatening noninfectious 
disease that humans encounter in addition to infectious 
diseases. Medicinal chemistry faces a difficult task in 
finding new/novel medications to combat this developing 
disease. The success of metal-based anticancer drug 
cisplatin has prompted young researchers to investigate 
more on the platinum-based complexes
8
. However, due 
to the various drawbacks of cisplatin and platinum-based 
agents, researchers have shifted their views towards other 
metal-based agents having higher cytotoxicity with 
minimum side effects
9-12
. In anticancer research, copper 
(II)-based compounds have emerged as promising 
candidates
13-15
. Copper metal ions have recently been 
employed to treat several disorders, including cancer, in a 
variety of inorganic pharmaceutical products
16
. Copper 
metal is also one of the bio-essential elements of the 
living system and it has been employed in a variety of 
medicinal therapies over the years
17
. 
In addition to metal ions, most ligands have biological 
properties of their own. They are the main constituents of 
metal complexes and play a major role in their 
stabilization. The chelation of ligands with metal ions has 
been shown to improve the biological activity of metal 
free ligands to some extent
18,19
. Metal complexes, on the 
other hand, have some limitations for usage as in-vivo 
medications due to their relatively high toxicity and 
limited water solubility
20,21
. To overcome these 
limitations, researchers have attempted to modify the 
ligand frameworks of metal complexes
22
.  
Given the above points, the present work aims to 
investigate the biological activity of two copper (II) 
complexes having N-donor chelating ligand. The 
selected complexes are highly soluble in water. Ligand 
also possesses several hydrogen bonding sites on its own. 
The biological importance of hydrogen bonding in 
regulating the growth of pathogenic microbes has been 
shown by a number of authors
23,24








of some copper (II) complexes containing N-donor 
ligands have already been reported by our research 
group
25
. In this paper, we report the antibacterial 
screening of two copper (II) complexes against human 
urinary pathogenic bacterial strains, Escherichia coli and 
Proteus mirabilis. The cytotoxicity of both the 
complexes on human adenocarcinoma cancer cells 
(HeLa) has also been reported in this paper.  
 
Materials and Methods 
The reagent and chemicals, used here, were of 
analytical grade. The copper (II) chloride dihydrate 
(CuCl2.2H2O), copper (II) bromide (CuBr2), and ligand 
dicyandiamide (C2N4H4) were purchased from Merck, 
India. The elemental analysis was determined using 
CHNS/O elemental analyzer, Perkin–Elmer- 
2400- Series ll. Magnetic susceptibility was determined 
using a Sherwood Magnetic Susceptibility balance at 
room temperature. Copper sulphate pentahydrate 
(CuSO4.5H2O) was used as a standard and Pascal's 
constants were used for diamagnetic corrections.  
 
Synthesis of the Complex 
 
dichloromono(1-amidino-O-ethylurea)copper (II), [Cu(AEtUH) 
Cl2].H2O ( Complex 1)  
The complex 1 was synthesized by refluxing the 
copper (II) chloride dihydrate (CuCl2.2H2O) and ligand 
dicyandiamide (C2N4H4) in a 1:1 stoichiometric ratio on 
a water bath for 3 h in ethanol solvent
26
. The resulting 
bright blue crystalline products were collected and 
thoroughly washed with ethanol, finally by acetone. 
 
bis(1-amidino-O-ethylurea)copper (II) bromide, [Cu(AEtUH)2]Br2  
(Complex 2) 
The complex 2 was synthesized by refluxing the 
ethanolic solutions of metal salt copper (II) bromide 
(CuBr2) and ligand dicyandiamide (C2N4H4) together in 
1:1 molar ratio at 45C on the water bath for about  
12 h
27
. Reaction mixture solution was filtered and the 
filtrate was kept for slow evaporation for few days. The 
resulting dark pink single crystals were collected and 
thoroughly washed with ethanol, finally by acetone.  
The schematic diagrams for the synthesis of 
complex 1 and 2 are shown in (Scheme 1). 
 
In vitro antibacterial screening 
The in vitro antibacterial screening of complexes 1 
and 2 was performed along with their corresponding 
metal salts (CuCl2.2H2O) and (CuBr2), and ligand 
(dicyandiamide), against two human uropathogenic 
Gram-negative bacterial strains, Escherichia coli and 
Proteus mirabilis. Filter disc diffusion method
28
 was 
used to screen the antibacterial activity using 
dimethylsulfoxide (DMSO) as a solvent. Experiments 
were done in triplicate and the resulting zone of 
inhibition corresponding to particular compounds 
were averaged and reported in the data.  
 
 
Scheme 1 — Schematic diagrams for the synthesis of complex1 
(A) and complex 2 (Hydrogen atoms are omitted for clarity) (B). 




Antibacterial screening of the test compounds was 
carried out in two different ways:  
(i)  Test compounds of same weight dissolved in equal 
volume: The minimum inhibitory concentrations 
(MICs) of all the test compounds were determined 
by the serial dilution method, within the range of 
(0.01-6.0 mg/mL). The sensitivity of bacteria to the 
test compounds was observed by measuring the 
diameter of the zone of inhibition of bacterial growth 
after 24 h incubation. The antibiotic gentamycin 
(0.01 mg/mL) was used as a positive control.  
(ii)  Test compounds of same equimolar concentration: 
In this case, MICs were determined for the 
complexes 1 and 2 only, within the concentration 
range (1.0-40.0 × 10
−3
 M).The sensitivity of bacteria 
to the complexes was evaluated and compared by 
extending the incubation time to 24 h, 48 h, and 72 h.  
 
In vitro cytotoxicity screening 
Cytotoxicity screening of the complexes 1 and 2 was 
evaluated by MTT assay
29
. Human adenocarcinoma 
cancer (HeLa) cells were first grown in T-25 culture 
flask and they were harvested by the trypsinization 
process. Cells were further plated by taking approximate 
density 1 × 10
5
 per well in the 96-well culture plates and 
then finally incubated for the confluency for 24 h.  
The medium from each well was removed and cells 
were washed with Dulbecco's Phosphate Buffer Saline 
and treated with an increasing amount of complexes. 
Each well containing 100 μL of different concentrations 
of complexes with serum-free DMEM was incubated for 
24 h in 5% CO2/95% air with relative humidity 90% at 
37±0.2°C. After incubation, all the contents were 
replaced by equal amounts of 1.2 mM serum-free 
DMEM containing MTT and further incubated for 
another 3 h. The viable cells formed certain kinds of 
formazan crystals. To solubilize the formazan grains the 
contents were further replaced by taking an equal 
amount of DMSO solvent. The absorbance value was 
recorded at 570 nm with the help of a multi-well plate 
reader –Infinite M200, Tecan. 
Statistical Analysis 
All the data reported in this paper were expressed 
as standard deviation (mean ± SD) of triplicate 
readings. One-way ANOVA, supplemented with 
Tukey’s HSD post hoc test, was used to perform the 
multiple comparisons between the groups which are 
more than two. To indicate the statistical significance, 
the values at P < 0.05 were considered. 
 
Results and Discussion 
 
Characterization of the complex 1 and 2 
Both complexes 1 and 2 were stable at room 
temperature and also highly soluble in water. Magnetic 
moment values and elemental (CHN) analysis data of 
the complex 1 and 2 are shown in (Table 1).Other 
characterizations, such as spectroscopic and 
electrochemical data of the complex 1 and single 





In vitro antibacterial screening 
Test compounds of same weight dissolved in equal 
volume: The results of the antibacterial screening of all 
test compounds are displayed in (Fig. 1 & 2). Data 
obtained indicate that, all the test compounds, except 
ligand, exhibited significant antibacterial activity against 
both bacterial strains, though at a considerably lower 
level than the antibiotic gentamycin. The bacterial 
growth inhibition potential (diameter of zone of 
inhibition) of all tested compounds was also found to be 
increased in a dose-dependent manner. While comparing 
the antibacterial effectiveness of the complexes 1 and 2 
with their respective metal salts (CuCl2.2H2O and 
CuBr2), complex 1 was more effective than its metal salt 
on both bacterial strains (Fig. 1A & B). The improved 
antibacterial effectiveness of complex1became more 
pronounced as their concentrations increased. MICs of 
the complex 1 and CuCl2.2H2O were found to be  
(0.01 and 0.5 mg/mL), respectively, against Escherichia 
coli, while they showed a similar MIC value  
(0.5 mg/mL), against Proteus mirabilis. In contrast to 
Table 1 — Elemental (CHN) analysis and magnetic moment data of the complex 1 and 2 
Compound Color Yield Analytical found (%) 
(calculated) (%) 
µeff (B.M.) 
Cu C H N  
[Cu(AEtUH)Cl2].H2O 
Complex 1 
Bright Blue 85 22.32 
(22.48) 
16.81 

















where AEtUH =1-amidino-O-ethylurea 




complex 1, the antibacterial effectiveness of complex 2 
was slightly lower than its metal salt on both bacterial 
strains (Fig. 2A & B). Their MICs were found to be  
(1.0 and 0.1 mg/mL), respectively, against Escherichia 
coli but they showed a similar MIC value (0.5 mg/mL), 
against Proteus mirabilis. 
Test compounds of same equimolar concentrations: 
The antibacterial screening of all test compounds on 
both bacterial strains was investigated further by taking 
the same equimolar concentrations (40 × 10
−3
 M). 
Incubation times were also extended to 24 h, 48 h and  
72 h (Table 2). When compared the antibacterial activity 
of all the test compounds to incubation time, their 
effectiveness decreased on average as the incubation 
time increased. The highest activity was shown by 24 h 
incubation. The ligand did not show any significant 
response during the entire incubation time. Complex 1 
was found to be more effective than its metal salt,  
where as complex 2 was found to be less effective than 
its metal salt. MICs of complexes 1 and 2 were 
compared further for all incubation times. Complex 1 
showed a similar MIC (5.0 × 10
−3
 M) on Escherichia 
coli during the entire incubation time, whereas 
somewhat different MICs (5.0 × 10
−3
 M) for 24 h and  
48 h, and (10.0 × 10
−3
 M) for 72 h, respectively,  
(Table 3). Complex 2 showed a similar MIC  
(10.0 × 10
−3
 M) on both bacterial strains during the 
entire incubation time (Table 4). The variations in the 
antibacterial activity of all tested compounds recorded 
after 24 h incubation are demonstrated in (Fig. 3A-D). 
Overall, the highest antibacterial activity among all of 
the test compounds is provided by complex 1. The exact 
mechanism of action of this complex is not certain. 
However, one  of  the  main  aspects that influences the  
 
 
Fig. 1 (A & B) — Histograms showing MIC values of complex 1, CuCl2.2H2O salt, ligand and positive control gentamycin at different 




Fig. 2 (A & B) — Histograms showing MIC values of complex 2, CuBr2 salt, ligand and positive control gentamycin at different 
concentrations against the bacterial strains (A) Escherichia coli; and (B) Proteus mirabilis, recorded at the end of 24 h 





Table 2 — aDiameter of inhibition zone of the test compounds 
Test compound 
(40 × 10−3 M) 
Escherichia coli  Proteus mirabilis 
24 h 48 h 72 h 24 h 48 h 72 h 
Ligand nil nil nil nil nil nil 
CuCl2.2H2O 19.0±0.0 17.3±7.0 15.0±0.0 21.0±0.0 17.7±0.0 17.0±0.0 
Complex 1 21.5±0.7 18.7±3.0 16.3±7.0 22.0±0.5 19.3±0.0 18.7±1.0 
CuBr2 22.3±0.9 20.7±0.9 18.0±0.9 22.3±0.9 20.7±0.9 20.0±0.9 
Complex 2 20.7±0.0 15.0±0.7 11.5±0.0 22.0±1.1 19.3±0.3 18.7±1.0 
aRepresents the diameter zone of inhibition of the test compounds after subtracting the inhibition zone value of DMSO solvent 
 
Table 3 — aDiameter of inhibition zone of the complex 1 for different concentrations 
Complex 1 
(10−3 M) 
Escherichia coli  Proteus mirabilis 
24 h 48 h 72 h 24h 48 h 72 h 
40 21.5±0.7 20.0±0.0 20.0±0.0 22.0±0.7 20.0±0.0 19.0±0.7 
20 18.0±0.0 15.5±0.5 15.5±0.3 16.5±0.5 14.5±0.3 14.5±0.0 
10 15.0±0.7 13.0±0.0 13.0±0.0 12.0±0.0 10.0±0.0 09.0±1.0 
05 09.0±0.0 09.0±0.0 09.0±0.0 07.0±0.0 07.0±0.0 nil 
01 nil nil nil nil nil nil 
aRepresents the diameter zone of inhibition of the complex 1 after subtracting the inhibition zone value of DMSO solvent 
 
Table 4 — aDiameter of inhibition zone of the complex 2 for different concentrations 
Complex 2 
(10−3 M) 
Escherichia coli  Proteus mirabilis 
24 h 48 h 72 h 24 h 48 h 72 h 
40 20.7±0.0 19.5±0.5 18.0±0.0 21.0±0.0 19.5±0.5 18.0±0.0 
20 18.0±0.7 13.5±0.5 10.0±0.0 15.0±0.7 13.5±0.5 10.0±0.5 
10 11.5±0.5 09.0±0.0 07.0±0.0 11.5±0.5 09.0±0.0 07.0±0.0 
05 nil nil nil nil nil nil 
01 nil nil nil nil nil nil 
aRepresents the diameter zone of inhibition of the complex 2 after subtracting the inhibition zone value of DMSO solvent 
 
antibacterial activity of test compounds is their lipophilic 
nature. According to ligand field theory (LFT), chelation  
of ligands with metal ions involves some overlap of 
ligand orbitals with metal ion orbitals. This orbital 
overlapping facilitates ligand electrons to delocalize to 
metal orbitals, lowering the positive charge (charge 
polarity) of the metal complexes. As a result, the 
lipophilic nature and cell penetration power of the metal 
complexes increase
6
. In complex 1, the presence of an 
N-donor chelating ligand as well as two monodentate 
chloride ligands might just have contributed to lowering 
its charge polarity, enhancing its lipophilicity. 
Furthermore, chloride ions, being labile in nature, can 
facilitate ligand substitution with bacterial biomolecules, 
enhancing the bactericidal effect of complex 1 in 
comparison to other test compounds. Schwartz et al., 
(2001) have also reported the role played by the labile 




Slight variations in the antibacterial efficiency of a 
particular test compound, on different bacterial strains, 
might be induced by differences in  bacterial  cell wall  
 
 
Fig. 3 (A-D) − Photographs showing the antibacterial activity 
(diameter of zone of inhibition) of tested compounds (40 × 1 0−3 M) 
against Escherichia coli and Proteus mirabilis recorded at the end of 
24 h; (A & B) Complex 1, parent CuCl2.2H2O salt and ligand 
dicyandiamide; (C & D) Complex 2, CuBr2 salt and ligand  
dicyandiamide 




permeability or bacterial ribosomal content
31
. Other 
aspects that may have influenced the antibacterial 
properties of test compounds include chemical structure, 
the total charge of the complex, type of the donor ligand, 




In vitro cytotoxicity screening 
The results of in vitro cytotoxicity of the complex 1 
and 2 against human cervical adenocarcinoma cancer 
(HeLa) cells were represented as the percentage (%)  
of viable cells. The relative number of surviving HeLa 
cells was decreased in a dose-dependent manner  
(Fig. 4A & B). The minimum concentration required to 
reduce the viable cancer cells by 50% (IC50) was 
calculated from dose-response curves. The complex 1 
was found to be more cytotoxic (IC50 = 59.64± 
6.68 µg/mL) than complex 2 (IC50 = 62.85±0.39 µg/mL). 
The variations in antiproliferative activity of the 
complexes 1 and 2 on HeLa cells can be attributed to 
differences in complex geometry and the nature of the 
metal-ligand bonds
35,36
. It has been reported that, 
anticancer property of a compound is significantly 
influenced by its strong DNA binding and breaking 
abilities
37-39
. Our research group has already reported the 
DNA binding capacities of some analogous copper (II) 
complexes
25
 and investigation into complex 1 is 
currently underway.  
 
Conclusion 
The biological properties of complexes 1 and 2 were 
screened in terms of antibacterial and cytotoxic activity. 
The antibacterial screening of complexes 1 and 2 was 
performed along with their corresponding metal salts, 
and ligand, against bacterial strains, Escherichia coli and 
Proteus mirabilis. All the test compounds, except ligand, 
have shown significant antibacterial activity on both 
bacterial strains. Their antibacterial effectiveness also 
increased in a dose dependent manner, whereas their 
ability to inhibit the growth of both bacterial species 
decreased as their incubation time increased. The 
activity of complex 1 was found to be greater than its 
metal salt, while complex 2 showed lower activity than 
the corresponding metal salt, on both bacterial species. 
Antiproliferative activity of complexes 1 and 2 against 
HeLa cancer cells was found to increase dose-
dependently. When comparing the cytotoxicity of the 
complexes, complex 1 was more cytotoxic than complex 
2, with IC50 values of 59.64±6.68 µg/mL and 
62.85±0.39 µg/mL, respectively. Observed changes in 
biological activity between complexes 1 and 2 can be 
attributed to differences in complex structures, nature of 
coordinating ligands, lipophilic nature, and DNA 
binding and breaking affinities. The most significant 
finding of this study is the remarkable antibacterial and 
cytotoxic activities of complex 1, which may provide a 
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Fig. 4 (A & B) — Histograms showing the cytotoxicity effect of the (A) complex 1; and (B) complex 2 against HeLa cells. Each bar 
represents the mean ± SD 
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